Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Biotech
Novartis to pay $1.1B upfront for Myricx to expand ADC pipeline
Novartis is pushing deeper into ADC development, paying $1.1 billion upfront to buy Myricx Bio for a pipeline based on a novel payload.
Nick Paul Taylor
Jul 6, 2026 5:10am
AstraZeneca's breast cancer pill boosts PFS by 56% in phase 3
Jun 2, 2025 7:10am
Enliven calls time on phase 1 HER2 solid tumor program
May 15, 2025 7:50am
Boehringer flexes staying power of HER2-mutant lung cancer med
Apr 28, 2025 9:00am
Eisai's abandoned Enhertu challenger set to live on at BlissBio
Mar 21, 2025 7:20am
Roche companion test moves into HER2-ultralow breast cancer
Feb 4, 2025 12:00pm
